Disease and allergy test kit supplier Omega Diagnostics swung to a first-half loss after it sold its legacy infectious disease division and closed its German and Indian manufacturing facilities. Pre-tax losses for the six months through September amounted to £0.33m, compared to a profit of £1.14m on-year. Revenue fell 15% to £4.46m, though on a continuing operations basis, revenue rose 6%. Omega Diagnostics said it was continuing to make progress in signing distribution agreements for its Visitect CD4 350 test kit for HIV, and had distributors in 19 countries. 'I am encouraged that we continue to make progress across all three divisions,' interim chairman William Rhodes said. 'Our financial performance was aligned to our expectations and is further indication that the restructuring we undertook in the prior year is having a positive impact.' 'The recent fundraise also provides us with sufficient funding to implement our short term strategies, and I would like to thank all our shareholders who participated.' 'In summary, we have continued to make progress against our plans, and are well positioned for near term growth in both our food intolerance and CD4 business units.'
Sign up to our
Subscribe to the latest investing news by entering your email address below
You can opt out at any time.
For five days a week you will get
- The latest company news
- Insight into investment trends
- Round-up of director's buys and sells
- Articles from Shares magazine
Plus more useful investment content and occasional promotional offers.
UK 350 Risers and Fallers
Tweets not available.